1. Home
  2. RLMD vs OPFI Comparison

RLMD vs OPFI Comparison

Compare RLMD & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • OPFI
  • Stock Information
  • Founded
  • RLMD 2004
  • OPFI 2009
  • Country
  • RLMD United States
  • OPFI United States
  • Employees
  • RLMD N/A
  • OPFI N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • OPFI Finance: Consumer Services
  • Sector
  • RLMD Health Care
  • OPFI Finance
  • Exchange
  • RLMD Nasdaq
  • OPFI Nasdaq
  • Market Cap
  • RLMD 289.7M
  • OPFI 288.7M
  • IPO Year
  • RLMD N/A
  • OPFI N/A
  • Fundamental
  • Price
  • RLMD $3.98
  • OPFI $9.80
  • Analyst Decision
  • RLMD Hold
  • OPFI Buy
  • Analyst Count
  • RLMD 2
  • OPFI 2
  • Target Price
  • RLMD $1.00
  • OPFI $11.75
  • AVG Volume (30 Days)
  • RLMD 1.8M
  • OPFI 778.7K
  • Earning Date
  • RLMD 11-13-2025
  • OPFI 10-29-2025
  • Dividend Yield
  • RLMD N/A
  • OPFI 2.54%
  • EPS Growth
  • RLMD N/A
  • OPFI N/A
  • EPS
  • RLMD N/A
  • OPFI 0.14
  • Revenue
  • RLMD N/A
  • OPFI $335,423,000.00
  • Revenue This Year
  • RLMD N/A
  • OPFI $119.75
  • Revenue Next Year
  • RLMD N/A
  • OPFI $10.98
  • P/E Ratio
  • RLMD N/A
  • OPFI $71.65
  • Revenue Growth
  • RLMD N/A
  • OPFI 28.69
  • 52 Week Low
  • RLMD $0.24
  • OPFI $6.44
  • 52 Week High
  • RLMD $4.34
  • OPFI $17.73
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 78.00
  • OPFI 47.91
  • Support Level
  • RLMD $2.42
  • OPFI $9.35
  • Resistance Level
  • RLMD $2.86
  • OPFI $10.25
  • Average True Range (ATR)
  • RLMD 0.43
  • OPFI 0.55
  • MACD
  • RLMD 0.15
  • OPFI 0.03
  • Stochastic Oscillator
  • RLMD 82.19
  • OPFI 40.67

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About OPFI OppFi Inc.

OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.

Share on Social Networks: